Researchers identified a severe outbreak of bivalve transmissible cancer in soft-shell clams in Puget Sound, with prevalence exceeding 75% by 2024. The disease was recently introduced from Atlantic Coast populations and was tracked using a new environmental DNA assay.
A study published in PNAS found that over 60% of pairs of damaging genetic variants can restore enzyme activity when combined, challenging long-held assumptions about genetics. This phenomenon, known as intragenic complementation, has implications for rare disease diagnosis and treatment.
Researchers at PNRI reveal how specific DNA rearrangements called inverted triplications contribute to the development of various genetic diseases. These complex rearrangements are caused by segments of DNA switching templates during the repair process, leading to disruptions in normal gene function and contributing to genetic disorders.
Researchers have discovered widespread genomic mutations and instability in transmissible cancers found in clams, which may explain their survival for over 200 years. The study highlights the clam's potential as a model for studying cancer evolution and developing novel strategies to block cancer in humans.
The Pacific Northwest Research Institute (PNRI) is partnering with Merck to develop a comprehensive plan to bring a promising antifungal agent from the laboratory to clinical practice. The compound has potential to reduce the burden of opportunistic infections in people living with HIV in developing countries.
Scientists at the Pacific Northwest Research Institute discovered evidence for DNA structure characteristic of metastasis in prostates with metastazing tumors. Early detection is crucial in fighting cancer, and this finding could lead to a new powerful weapon against cancer spread.
A new DNA test using Fourier transform-infrared spectroscopy has been developed to identify patients with myelodysplasia (MDS) or those at high risk of developing the disease. The test is highly predictive and can distinguish MDS patients from those with non-malignant bone marrow disorders.
A new blood test has been developed to detect mesothelioma, a type of cancer caused by asbestos exposure. The test, which identifies specific molecular markers in the blood, shows promise for early detection and monitoring, potentially improving treatment outcomes.
A new biomarker, HE4, has been identified as a potential tool for early detection of ovarian cancer. The molecule is secreted into the blood and its presence can be detected in simple clinical tests.
A new technique developed by Malins' laboratory uses Fourier transform-infrared spectroscopy to analyze DNA from prostate tumor biopsies, allowing doctors to identify patients at high risk for metastasis. This breakthrough enables more informed treatment decisions and potentially saves lives.